A single-center prospective randomized controlled trial for tiggio combined with oxaliplatin (SOX) versus capecitabine combined with oxaliplatin (XELOX) in the treatment of postoperative adjuvant chemotherapy in patients with colorectal cancer
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Interventions: Group 1:SOX;Group 2:XELOX Primary outcome(s): 3 years disease free survival rate Study Design: Randomized parallel controlled trial
创建时间：
2018-12-15
